GLENMARK - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 3.2
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry zones could be between ₹2,350 - ₹2,375, exploiting the immediate support level offered by the 50-DMA and leveraging the sustained high volume. A stop-loss order should be placed just below the recent swing low around ₹2,185 to mitigate downside risk. The overall trend remains bullish, but the premium valuation warrants careful monitoring of momentum development; a break below ₹2,350 would signal increased vulnerability.
✅ Positive
The price is currently holding above the 50-DMA and 200-DMA, indicating underlying support. Volume has been consistently high over the past week, suggesting sustained interest in the stock. There’s a clear upward trend visible from the recent low of ₹1,793.
⚠️ Limitation
The high Stock P/E of 46.0 relative to the industry PE of 34.8 suggests a premium valuation that could be vulnerable to profit-taking if growth expectations aren't met. Furthermore, while volume is elevated, it’s not generating significant momentum beyond its current level, and the RSI at 57.9 shows considerable buying pressure but isn't in overbought territory.
📉 Company Negative News
The recent NDTV Profit article highlights Glenmark Pharma’s launch of GLIPIQ® with a starting price of ₹325, which is positive for revenue generation, but doesn't immediately translate to significant chart-based momentum signals.
🏭 Industry
The pharmaceutical sector generally enjoys strong growth driven by aging populations and increased healthcare spending. However, within the industry, smaller biotech companies often face valuation challenges due to higher risk profiles compared to established players. Glenmark's recent launch provides a positive catalyst but is contingent on market adoption rates.